During the past few years, several genetic aberrations that may contribute to increased risks for development of breast and/ or ovarian cancers have been identified. The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast and Ovarian focus specifically on the assessment of genetic mutations in BRCA1/BRCA2, TP53, and PTEN, and recommend approaches to genetic testing/counseling and management strategies in individuals with these mutations. This portion of the NCCN Guidelines includes recommendations regarding diagnostic criteria and management of patients with Cowden Syndrome/ PTEN hamartoma tumor syndrome.
|Original language||English (US)|
|Number of pages||13|
|Journal||JNCCN Journal of the National Comprehensive Cancer Network|
|State||Published - Sep 1 2014|
ASJC Scopus subject areas